Start-Up Spotlight: Elypta Targets World’s First Metabolism-Based Early Cancer Diagnosis
Chalmers University of Technology spin out takes a different route to cancer biomarker identification
Executive Summary
The Swedish liquid biopsy start-up expects to be the first company to secure US FDA approval for a metabolism-based urine test for the early detection of kidney cancer in post-surgery patients.
You may also be interested in...
Olympus Medical Follows The Patient Pathway In New Strategic Plan
Having divested non-medical imaging a year ago, Olympus Corp is putting its foot to the floor in refocusing on its medical portfolio. It has set global ambitions of strengthening its coverage of unmet needs and of playing a major role in reshaping health care delivery.
Olympus Medical Follows The Patient Pathway In New Strategic Plan
Having divested non-medical imaging a year ago, Olympus Corp is putting its foot to the floor in refocusing on its medical portfolio. It has set global ambitions of strengthening its coverage of unmet needs and of playing a major role in reshaping health care delivery.
Cardio Industry Puts Weight Behind UK Call For National CVD Strategy
Better uptake of medtech in tackling cardiovascular disease can bring benefits across the entire pathway of care, say UK CVD companies, who are urging the government to improve levels of technology adoption.